Premenstrual dysphoric disorder

被引:1
|
作者
Schwenkhagen A. [1 ]
Schaudig K. [1 ]
机构
[1] Praxis für gynäkologische Endokrinologie, HORMONE HAMBURG, Gynaekologicum Hamburg, Altonaerstr. 59, Hamburg
关键词
Contraceptives; oral; combined; Luteal phase; PMDD; Premenstrual syndrome; Selective serotonin reuptake inhibitors;
D O I
10.1007/s10304-015-0035-1
中图分类号
学科分类号
摘要
Many women of reproductive age complain about some premenstrual discomfort. Mood and behavioral symptoms, such as depression or anxiety, and somatic symptoms, such as breast tenderness, may be present. However, only a minority of women meet the criteria for PMDD (premenstrual dysphoric disorder), the most severe form of premenstrual syndrome (PMS), causing substantial distress or functional impairment. The complex pathophysiology of PMDD is not completely understood. As a basis for diagnosis, symptoms should be recorded using prospective daily charting for 2 months. It is mandatory to eliminate other possible diagnoses. Treatment should be tailored according to symptomatology. First-line therapies include serotonin reuptake inhibitors, taken either throughout the whole cycle or during the luteal phase only, and combined hormonal contraceptives with shortened hormone-free intervals or continuously. © 2015, Springer-Verlag Berlin Heidelberg.
引用
收藏
页码:245 / 256
页数:11
相关论文
共 50 条
  • [31] Premenstrual dysphoric disorder: Literature review
    Fryer C.P.
    Kaspi S.P.
    Fallon S.K.
    Moline M.L.
    Severino S.K.
    Archives of Women's Mental Health, 1999, 2 (1) : 1 - 27
  • [32] Easing the burden of premenstrual dysphoric disorder
    Omole, Folashade
    Hacker, Yolanda
    Patterson, Eltanya
    Isang, Mercy
    Bell-Carter, Denise
    JOURNAL OF FAMILY PRACTICE, 2013, 62 (01) : E1 - E7
  • [33] YAZ® in the treatment of premenstrual dysphoric disorder
    Rapkin, Andrea J.
    JOURNAL OF REPRODUCTIVE MEDICINE, 2008, 53 (09) : 729 - 741
  • [34] The pharmacotherapeutic management of premenstrual dysphoric disorder
    Ciccone, Nancy
    Kovacheff, Maya B.
    Frey, Benicio N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (01) : 145 - 151
  • [35] The pharmacologic management of premenstrual dysphoric disorder
    Rapkin, Andrea J.
    Winer, Sharon A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (03) : 429 - 445
  • [36] Premenstrual dysphoric disorder (PMDD) - an overview
    Battey, R. M.
    SA PHARMACEUTICAL JOURNAL, 2023, 90 (04) : 29 - 32
  • [37] Premenstrual syndrome and premenstrual dysphoric disorder-Overview on pathophysiology, diagnostics and treatment
    Haussmann, Jana
    Goeckenjan, M.
    Haussmann, R.
    Wimberger, P.
    NERVENARZT, 2024, : 268 - 274
  • [38] Premenstrual Syndrome and Premenstrual Dysphoric Disorder in Japanese Collegiate Athletes
    Takeda, Takashi
    Imoto, Yoko
    Nagasawa, Hiroyo
    Muroya, Miyuki
    Shiina, Masami
    JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY, 2015, 28 (04) : 215 - 218
  • [39] New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder
    Eriksson E.
    Endicott J.
    Andersch B.
    Angst J.
    Demyttenaere K.
    Facchinetti F.
    Lanczik M.
    Montgomery S.
    Muscettola G.
    O'Brien P.M.S.
    Studd J.
    Sundblad C.
    Young A.H.
    Archives of Women's Mental Health, 2002, 4 (4) : 111 - 119
  • [40] Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women
    Takeda, T.
    Tasaka, K.
    Sakata, M.
    Murata, Y.
    ARCHIVES OF WOMENS MENTAL HEALTH, 2006, 9 (04) : 209 - 212